These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16260906)

  • 1. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?
    Sabine C;
    AIDS; 2005 Nov; 19(17):1995-2000. PubMed ID: 16260906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
    d'Arminio Monforte A; Sabin CA; Phillips A; Sterne J; May M; Justice A; Dabis F; Grabar S; Ledergerber B; Gill J; Reiss P; Egger M;
    Arch Intern Med; 2005 Feb; 165(4):416-23. PubMed ID: 15738371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
    Murphy EL; Collier AC; Kalish LA; Assmann SF; Para MF; Flanigan TP; Kumar PN; Mintz L; Wallach FR; Nemo GJ;
    Ann Intern Med; 2001 Jul; 135(1):17-26. PubMed ID: 11434728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
    Mocroft A; Gatell J; Reiss P; Ledergerber B; Kirk O; Vella S; Blaxhult A; Phillips AN; Lundgren J;
    AIDS; 2004 Nov; 18(17):2333-7. PubMed ID: 15577550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
    Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
    Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
    May M; Sterne JA; Sabin C; Costagliola D; Justice AC; Thiébaut R; Gill J; Phillips A; Reiss P; Hogg R; Ledergerber B; D'Arminio Monforte A; Schmeisser N; Staszewski S; Egger M;
    AIDS; 2007 May; 21(9):1185-97. PubMed ID: 17502729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004.
    Schneider MF; Gange SJ; Williams CM; Anastos K; Greenblatt RM; Kingsley L; Detels R; Muñoz A
    AIDS; 2005 Nov; 19(17):2009-18. PubMed ID: 16260908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.
    Anastos K; Barrón Y; Miotti P; Weiser B; Young M; Hessol N; Greenblatt RM; Cohen M; Augenbraun M; Levine A; Muñoz A;
    Arch Intern Med; 2002 Sep; 162(17):1973-80. PubMed ID: 12230420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
    Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
    Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
    Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
    AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.